These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 24311643)

  • 1. Phase II study of everolimus in children and adults with neurofibromatosis type 2 and progressive vestibular schwannomas.
    Karajannis MA; Legault G; Hagiwara M; Giancotti FG; Filatov A; Derman A; Hochman T; Goldberg JD; Vega E; Wisoff JH; Golfinos JG; Merkelson A; Roland JT; Allen JC
    Neuro Oncol; 2014 Jan; 16(2):292-7. PubMed ID: 24311643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II trial of lapatinib in adult and pediatric patients with neurofibromatosis type 2 and progressive vestibular schwannomas.
    Karajannis MA; Legault G; Hagiwara M; Ballas MS; Brown K; Nusbaum AO; Hochman T; Goldberg JD; Koch KM; Golfinos JG; Roland JT; Allen JC
    Neuro Oncol; 2012 Sep; 14(9):1163-70. PubMed ID: 22844108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of mTORC1 inhibition by everolimus in neurofibromatosis type 2 patients with growing vestibular schwannomas.
    Goutagny S; Raymond E; Esposito-Farese M; Trunet S; Mawrin C; Bernardeschi D; Larroque B; Sterkers O; Giovannini M; Kalamarides M
    J Neurooncol; 2015 Apr; 122(2):313-20. PubMed ID: 25567352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imaging as an early biomarker to predict sensitivity to everolimus for progressive NF2-related vestibular schwannoma.
    Nghiemphu PL; Vitte J; Dombi E; Nguyen T; Wagle N; Ishiyama A; Sepahdari AR; Cachia D; Widemann BC; Brackmann DE; Doherty JK; Kalamarides M; Giovannini M
    J Neurooncol; 2024 Apr; 167(2):339-348. PubMed ID: 38372904
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Erlotinib for progressive vestibular schwannoma in neurofibromatosis 2 patients.
    Plotkin SR; Halpin C; McKenna MJ; Loeffler JS; Batchelor TT; Barker FG
    Otol Neurotol; 2010 Sep; 31(7):1135-43. PubMed ID: 20736812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase 0 Clinical Trial of Everolimus in Patients with Vestibular Schwannoma or Meningioma.
    Karajannis MA; Mauguen A; Maloku E; Xu Q; Dunbar EM; Plotkin SR; Yaffee A; Wang S; Roland JT; Sen C; Placantonakis DG; Golfinos JG; Allen JC; Vitanza NA; Chiriboga LA; Schneider RJ; Deng J; Neubert TA; Goldberg JD; Zagzag D; Giancotti FG; Blakeley JO
    Mol Cancer Ther; 2021 Sep; 20(9):1584-1591. PubMed ID: 34224367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanism-based modeling of the clinical effects of bevacizumab and everolimus on vestibular schwannomas of patients with neurofibromatosis type 2.
    Ouerdani A; Goutagny S; Kalamarides M; Trocóniz IF; Ribba B
    Cancer Chemother Pharmacol; 2016 Jun; 77(6):1263-73. PubMed ID: 27146400
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multicenter, Prospective, Phase II and Biomarker Study of High-Dose Bevacizumab as Induction Therapy in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannoma.
    Plotkin SR; Duda DG; Muzikansky A; Allen J; Blakeley J; Rosser T; Campian JL; Clapp DW; Fisher MJ; Tonsgard J; Ullrich N; Thomas C; Cutter G; Korf B; Packer R; Karajannis MA
    J Clin Oncol; 2019 Dec; 37(35):3446-3454. PubMed ID: 31626572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of lapatinib on meningioma growth in adults with neurofibromatosis type 2.
    Osorio DS; Hu J; Mitchell C; Allen JC; Stanek J; Hagiwara M; Karajannis MA
    J Neurooncol; 2018 Sep; 139(3):749-755. PubMed ID: 29948766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A 4-year phase II study of everolimus in NF2 patients with growing vestibular schwannomas.
    Goutagny S; Giovannini M; Kalamarides M
    J Neurooncol; 2017 Jun; 133(2):443-445. PubMed ID: 28434114
    [No Abstract]   [Full Text] [Related]  

  • 11. A phase II study of continuous oral mTOR inhibitor everolimus for recurrent, radiographic-progressive neurofibromatosis type 1-associated pediatric low-grade glioma: a Neurofibromatosis Clinical Trials Consortium study.
    Ullrich NJ; Prabhu SP; Reddy AT; Fisher MJ; Packer R; Goldman S; Robison NJ; Gutmann DH; Viskochil DH; Allen JC; Korf B; Cantor A; Cutter G; Thomas C; Perentesis JP; Mizuno T; Vinks AA; Manley PE; Chi SN; Kieran MW
    Neuro Oncol; 2020 Oct; 22(10):1527-1535. PubMed ID: 32236425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: a retrospective review of 31 patients.
    Plotkin SR; Merker VL; Halpin C; Jennings D; McKenna MJ; Harris GJ; Barker FG
    Otol Neurotol; 2012 Aug; 33(6):1046-52. PubMed ID: 22805104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bevacizumab induces regression of vestibular schwannomas in patients with neurofibromatosis type 2.
    Mautner VF; Nguyen R; Kutta H; Fuensterer C; Bokemeyer C; Hagel C; Friedrich RE; Panse J
    Neuro Oncol; 2010 Jan; 12(1):14-8. PubMed ID: 20150363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suggested response criteria for phase II antitumor drug studies for neurofibromatosis type 2 related vestibular schwannoma.
    Plotkin SR; Halpin C; Blakeley JO; Slattery WH; Welling DB; Chang SM; Loeffler JS; Harris GJ; Sorensen AG; McKenna MJ; Barker FG
    J Neurooncol; 2009 May; 93(1):61-77. PubMed ID: 19430883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medical treatment in neurofibromatosis type 2. Review of the literature and presentation of clinical reports.
    Goutagny S; Kalamarides M
    Neurochirurgie; 2018 Nov; 64(5):370-374. PubMed ID: 28162254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bevacizumab decreases vestibular schwannomas growth rate in children and teenagers with neurofibromatosis type 2.
    Hochart A; Gaillard V; Baroncini M; André N; Vannier JP; Vinchon M; Dubrulle F; Lejeune JP; Vincent C; Nève V; Sudour Bonnange H; Bonne NX; Leblond P
    J Neurooncol; 2015 Sep; 124(2):229-36. PubMed ID: 26022982
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multicenter, prospective, phase II study of maintenance bevacizumab for children and adults with NF2-related schwannomatosis and progressive vestibular schwannoma.
    Plotkin SR; Allen J; Dhall G; Campian JL; Clapp DW; Fisher MJ; Jain RK; Tonsgard J; Ullrich NJ; Thomas C; Edwards LJ; Korf B; Packer R; Karajannis MA; Blakeley JO
    Neuro Oncol; 2023 Aug; 25(8):1498-1506. PubMed ID: 37010875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I study of everolimus in pediatric patients with refractory solid tumors.
    Fouladi M; Laningham F; Wu J; O'Shaughnessy MA; Molina K; Broniscer A; Spunt SL; Luckett I; Stewart CF; Houghton PJ; Gilbertson RJ; Furman WL
    J Clin Oncol; 2007 Oct; 25(30):4806-12. PubMed ID: 17947729
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term follow-up studies of Gamma Knife surgery for patients with neurofibromatosis Type 2.
    Sun S; Liu A
    J Neurosurg; 2014 Dec; 121 Suppl():143-9. PubMed ID: 25434947
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Biomarker Study of Bevacizumab for Hearing Loss Resulting From Neurofibromatosis Type 2-Associated Vestibular Schwannomas.
    Blakeley JO; Ye X; Duda DG; Halpin CF; Bergner AL; Muzikansky A; Merker VL; Gerstner ER; Fayad LM; Ahlawat S; Jacobs MA; Jain RK; Zalewski C; Dombi E; Widemann BC; Plotkin SR
    J Clin Oncol; 2016 May; 34(14):1669-75. PubMed ID: 26976425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.